QUEBEC CITY, July 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 7th International Congress of Neuroendocrinology, which will be held July 11 through 15, 2010, in Rouen, France. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.Poster Title: "Use of the Orally Active Ghrelin Mimetic AEZS-130 as a Simple Test for the Diagnosis of Growth Hormone (GH) Deficiency (GHD) in adults (AGHD)", Merriam G.R., Yuen K., Bonert V., Dobs A, Garcia J., Kipnes M., Molitch M., Swerdloff R., Wang C., Cook d., Altemose I. and Biller B. Presenter: George R. Merriam, M.D., Professor of Medicine, University of Washington Date and Time: Wednesday, July 14, 2010, 3:30 pm -6 pm (local time) Poster Board #: P2-98 Location: Law Faculty, Universite de Rouen
SOURCE AETERNA ZENTARIS INC.